Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|March 24, 2026

The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?

Today’s podcast spotlights major funding and a high-profile deal surrounding emerging multispecific immune-engaging biologics that demonstrate improved targeting precision and safety control across complex oncology and autoimmune indications.

Welcome to The BioPharm Brief, your daily snapshot of key developments shaping biopharmaceutical innovation and clinical strategy. Today’s update highlights continued momentum in next-generation T-cell engager platforms, driven by both early-stage financing and large biopharma partnerships targeting complex diseases.

First, Excalipoint Therapeutics has launched with $68.7 million in seed financing to advance a portfolio of multi-specific T-cell engager platforms. The company is developing several proprietary technologies designed to overcome longstanding challenges in T-cell engager therapies, particularly in solid tumors, for which issues such as limited tumor penetration and immunosuppressive microenvironments have constrained efficacy. Its pipeline includes multiple programs across oncology and immunology, supported by platform approaches aimed at improving selectivity, durability, and safety of immune activation. The financing reflects strong investor confidence in next-generation immuno-oncology strategies that expand beyond hematologic cancers into more difficult-to-treat indications.

In parallel, Kali Therapeutics has entered a global licensing agreement with biopharma major Sanofi for its tri-specific T-cell engager candidate, KT501, highlighting continued interest from large biopharmaceutical companies in advanced biologic platforms. Under the agreement, Sanofi gains worldwide rights to the therapy, which is designed to target multiple B-cell antigens simultaneously for the treatment of autoimmune diseases. The deal includes significant upfront and milestone payments, underscoring the perceived value of multi-specific immune-modulating therapies. KT501 incorporates a CD3-targeting mechanism alongside additional antigen binding to enable broader B-cell depletion while aiming to manage cytokine-related toxicity, a key challenge in T-cell engager development.

Together, these developments reflect a broader industry shift toward multi-specific biologics engineered for greater precision and control of immune responses. As both startups and large biopharmaceutical companies invest in these platforms, T-cell engager technologies are expanding beyond oncology into autoimmune disease applications, signaling a widening therapeutic scope.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments

  • Excalipoint’s $68.7 million launch supports next-generation T-cell engager platform development.
  • Kali Therapeutics’ deal with Sanofi highlights strong pharma interest in multi-specific immune therapies.
  • T-cell engager technologies are expanding into both oncology and autoimmune disease treatment strategies.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more